Lymphoma | Topics

 
Lenalidomide Plus Rituximab Continues to Improve PFS With Manageable Safety in Lymphoma Subtypes
June 13, 2021

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Zandelisib/Zanubrutinib Combination in R/R CLL and B-Cell Malignancies Shows Clinical Benefit
June 12, 2021

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Liso-Cel Meets Primary End Point of Event-Free Survival Improvement in Phase 3 Trial
June 10, 2021

The CAR T-cell therapy lisocabtagene maraleucel resulted in better efficacy versus standard of care with no new safety signals.